Keros Therapeutics, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value
Keros Therapeutics, Inc. (KROS) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value of $11.00 per share for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue · last filed 2026-08-03
- Keros Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2026-03-31 was $11.19.
- Keros Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2025-03-31 was $0.00, a 100.00% decline year-over-year.
- Keros Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2024-03-31 was $40.72, a 4.36% increase year-over-year.
- Keros Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2023-03-31 was $39.02, a 15.99% increase year-over-year.
- Keros Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2025 was $10.36, a 74.68% decline from fiscal 2024.
- Keros Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2024 was $40.92, a 16.12% increase from fiscal 2023.
- Keros Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2023 was $35.24, a 13.02% increase from fiscal 2022.
- Keros Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2022 was $31.18, a 26.27% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 12 month |
|---|---|---|---|---|
| 2026-06-30 | $11.00 10-Q · filed 2026-08-03 | |||
| 2026-03-31 | $11.19 10-Q · filed 2026-05-14 | |||
| 2025-12-31 | $10.36 10-K · filed 2026-03-04 | |||
| 2025-09-30 | $10.36 10-Q · filed 2025-11-05 | |||
| 2025-06-30 | $10.36 10-Q · filed 2026-08-03 | |||
| 2025-03-31 | $0.00 10-Q · filed 2026-05-14 | |||
| 2024-12-31 | $40.92 10-K · filed 2026-03-04 | |||
| 2024-09-30 | $40.11 10-Q · filed 2025-11-05 | |||
| 2024-06-30 | $40.62 10-Q · filed 2025-08-06 | |||
| 2024-03-31 | $40.72 10-Q · filed 2025-05-06 | |||
| 2023-12-31 | $35.24 10-K · filed 2025-02-26 | |||
| 2023-09-30 | $36.05 10-Q · filed 2024-11-06 | |||
| 2023-06-30 | $36.96 10-Q · filed 2024-08-07 | |||
| 2023-03-31 | $39.02 10-Q · filed 2024-05-08 | |||
| 2022-12-31 | $31.18 10-K · filed 2025-02-26 | |||
| 2022-09-30 | $31.42 10-Q · filed 2023-11-06 | |||
| 2022-06-30 | $32.17 10-Q · filed 2023-08-07 | |||
| 2022-03-31 | $33.64 10-Q · filed 2023-05-04 | |||
| 2021-12-31 | $42.29 10-K · filed 2023-03-03 | |||
| 2021-09-30 | $42.92 10-Q · filed 2022-11-03 | |||
| 2021-06-30 | $47.10 10-Q · filed 2022-08-04 | |||
| 2021-03-31 | $49.15 10-Q · filed 2022-05-05 | |||
| 2020-12-31 | $15.57 10-K · filed 2022-03-09 | |||
| 2020-09-30 | $14.78 10-Q · filed 2021-11-04 | |||
| 2020-06-30 | $14.24 10-Q · filed 2021-08-05 | |||
| 2020-03-31 | $49.15 10-Q · filed 2021-05-06 | |||
| 2019-12-31 | $0.32 10-K · filed 2021-03-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| NATURES SUNSHINE PRODUCTS INC (NATR) | United States | $0.228B | 20.51 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| Whitehawk Therapeutics, Inc. (WHWK) | United States | $0.221B | |
| Eledon Pharmaceuticals, Inc. (ELDN) | United States | $0.219B | -3.23 |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |